Karen L. Parkhill, insider at Medtronic

Karen L. Parkhill Insider Information

CFO of Medtronic
Karen Parkhill is Executive Vice President and Chief Financial Officer of Medtronic. She serves on the company's Executive Committee and is responsible for leading the Medtronic global finance organization and key supporting functions, including Treasury, Controller, Tax, Internal Audit, Investor Relations, Corporate Strategy, and Business Development. In late 2020, she assumed leadership of the IT and Enterprise Excellence organizations as well. In addition, Karen serves as the Executive Sponsor of the Medtronic PRIDE Employee Resource Group and Women’s Network “Commit to Connect” leadership program, which supports senior women leadership development at Medtronic.

Karen joined Medtronic from Comerica Incorporated in June 2016 where she was Vice Chairman and Chief Financial Officer. She was a member of Comerica's Management Executive Committee and the Comerica Bank Board of Directors. Prior to Comerica, Karen was at JPMorgan Chase and Co., where she served as Chief Financial Officer for the Commercial Banking business from 2007 to 2011. She joined JPMorgan in 1992 in the Investment Bank and held various positions of increasing scope and responsibility.

Karen currently sits on the Board of Directors at American Express. She previously served as a member of the International Women’s Forum, as a National Trustee for the Boys and Girls Club of America, the Board of Directors of Methodist Health System, and the Executive Board for Southern Methodist University Cox School of Business. In early 2021, Karen was ranked as the No. 2 Women Leader in Medical Devices by the Healthcare Technology Report. She was named among American Banker’s “The 25 Most Powerful Women in Banking” in 2015, and “The 25 Women to Watch” in 2011 and 2013. Karen earned bachelor's degrees in business administration and mathematics from Southern Methodist University in Dallas and an MBA from the University of Chicago Booth School of Business. She is a 2012 recipient of the SMU Cox School of Business Distinguished Alumni Award and a 2008 recipient of the University of Chicago Booth School of Business Distinguished Young Alumna Award.

What is Karen L. Parkhill's net worth?

The estimated net worth of Karen L. Parkhill is at least $8.33 million as of September 15th, 2020. Ms. Parkhill owns 87,366 shares of Medtronic stock worth more than $8,326,853 as of August 17th. This net worth approximation does not reflect any other assets that Ms. Parkhill may own. Additionally, Ms. Parkhill receives a salary of $3,290,000.00 as CFO at Medtronic. Learn More about Karen L. Parkhill's net worth.

How old is Karen L. Parkhill?

Ms. Parkhill is currently 57 years old. There are 4 older executives and no younger executives at Medtronic. The oldest executive at Medtronic is Mr. Ivan K. Fong, Exec. VP, Gen. Counsel & Sec., who is 61 years old. Learn More on Karen L. Parkhill's age.

What is Karen L. Parkhill's salary?

As the CFO of Medtronic plc, Ms. Parkhill earns $3,290,000.00 per year. The highest earning executive at Medtronic is Mr. Geoffrey Straub Martha, Chairman & CEO, who commands a salary of $4,090,000.00 per year. Learn More on Karen L. Parkhill's salary.

How do I contact Karen L. Parkhill?

The corporate mailing address for Ms. Parkhill and other Medtronic executives is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. Medtronic can also be reached via phone at (531) 438-1700 and via email at [email protected] Learn More on Karen L. Parkhill's contact information.

Has Karen L. Parkhill been buying or selling shares of Medtronic?

Karen L. Parkhill has not been actively trading shares of Medtronic during the last quarter. Learn More on Karen L. Parkhill's trading history.

Who are Medtronic's active insiders?

Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Geoffrey Martha (CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.

Are insiders buying or selling shares of Medtronic?

During the last year, Medtronic insiders bought shares 1 times. They purchased a total of 5,010 shares worth more than $517,332.60. During the last year, insiders at the medical technology company sold shares 8 times. They sold a total of 154,504 shares worth more than $19,898,744.52. The most recent insider tranaction occured on March, 18th when CFO Karen L Parkhill sold 682 shares worth more than $75,020.00. Insiders at Medtronic own 0.5 % of the company. Learn More about insider trades at Medtronic.

Information on this page was last updated on 3/18/2022.

Karen L. Parkhill Insider Trading History at Medtronic

See Full Table

Karen L. Parkhill Buying and Selling Activity at Medtronic

This chart shows Karen L. Parkhill's buying and selling at Medtronic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medtronic Company Overview

Medtronic logo
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $95.31
Low: $94.61
High: $95.56

50 Day Range

MA: $91.03
Low: $87.40
High: $96.04

2 Week Range

Now: $95.31
Low: $86.70
High: $135.89

Volume

3,636,602 shs

Average Volume

4,681,681 shs

Market Capitalization

$127.86 billion

P/E Ratio

25.55

Dividend Yield

2.86%

Beta

0.75